110 related articles for article (PubMed ID: 22270402)
21. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
Salah-Eldin MA; Ebrahim MA; El-Sadda W
Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
[TBL] [Abstract][Full Text] [Related]
22. Increased levels of tumor necrosis factor-α involved in rituximab-related acute pulmonary fibrosis in diffuse large B-cell lymphoma.
Zhang X; Guo X; Pan J
Am J Clin Pathol; 2015 May; 143(5):725-7. PubMed ID: 25873507
[TBL] [Abstract][Full Text] [Related]
23. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
24. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type.
Fenot M; Quereux G; Brocard A; Renaut JJ; Dreno B
Eur J Dermatol; 2010; 20(6):753-7. PubMed ID: 20956100
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
[TBL] [Abstract][Full Text] [Related]
26. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298
[TBL] [Abstract][Full Text] [Related]
27. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
28. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
29. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials.
Seidemann K; Meyer U; Jansen P; Yakisan E; Rieske K; Führer M; Kremens B; Schrappe M; Reiter A
Klin Padiatr; 1998; 210(4):279-84. PubMed ID: 9743966
[TBL] [Abstract][Full Text] [Related]
30. [Acute tumor lysis syndrome due to mono-therapy with a corticosteroid in a patient with non-Hodgkin lymphoma].
Wester JP; Breumelhof R; Geers AB; Meuwissen OJ
Ned Tijdschr Geneeskd; 1997 Aug; 141(33):1621-3. PubMed ID: 9543767
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
Feng J; Wu J; Song Y; Su L; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Ouyang X; Li X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):309-13. PubMed ID: 24759018
[TBL] [Abstract][Full Text] [Related]
33. Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Park S; Han B; Cho JW; Woo SY; Kim S; Kim SJ; Kim WS
Nutr Cancer; 2014; 66(2):225-33. PubMed ID: 24405259
[TBL] [Abstract][Full Text] [Related]
34. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
[TBL] [Abstract][Full Text] [Related]
35. Primary diffuse large B cell lymphoma of the base of tongue.
Lim JH; Lim JY; Kim YM; Kim CS; Choi SJ; Yi HG; Choi WG; Lee MH
J Cancer Res Ther; 2012; 8(1):135-7. PubMed ID: 22531534
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma.
Lipstein M; O'Connor O; Montanari F; Paoluzzi L; Bongero D; Bhagat G
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):E43-6. PubMed ID: 21856550
[TBL] [Abstract][Full Text] [Related]
37. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
38. Natural history of follicular grade 3 non-Hodgkin's lymphoma.
Bierman PJ
Curr Opin Oncol; 2007 Sep; 19(5):433-7. PubMed ID: 17762566
[TBL] [Abstract][Full Text] [Related]
39. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
[TBL] [Abstract][Full Text] [Related]
40. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]